Electromed, Inc. (NASDAQ: ELMD) today announced financial results for the three months and fiscal year ended June 30, 2011. Net revenues for the three months ended June 30, 2011 were approximately $4,954,000, a 36.7% increase compared to net revenues of approximately $3,624,000 for the same period last year. Net revenues for the fiscal year ended June 30, 2011 were approximately $19,004,000, a 32.9% increase compared to net revenues of approximately $14,304,000 for the same period last year.

The Company also announced net income of approximately $165,000, or $0.02 per basic and diluted share, for the three months ended June 30, 2011, compared to net income of approximately $71,000, or $0.01 per basic and diluted share, for the same three-month period last year. For the fiscal year ended June 30, 2011, net income was $1,056,000, or $0.14 per basic and $0.13 per diluted share, compared to net income of approximately $916,000, or $0.15 per basic and diluted share, for the same period last year. Net revenues increased primarily due to an expansion of the sales force. Net income results were attributable to higher net revenues, offset by expenses related to increases in sales force, support and production personnel, and an expansion of marketing and research and development activities. In addition, earnings per share were affected by an increase to the number of outstanding shares of Company common stock as compared to the prior-year periods, which was attributable to the Company’s completion of its initial public offering in August 2010. Including the underwriter’s over-allotment option, a total of 1,900,000 shares of Company common stock were registered and sold in the initial public offering.

Robert Hansen, Chairman and CEO, commented on the Company, saying,

“Electromed, Inc. is a rapidly growing company. It is using a portion of the capital received from its IPO to grow its sales force and support its infrastructure. We believe these actions are essential investments in driving longer-term profitable results. We have also continued to make important investments in research and development. We believe that new innovations are the surest path to sustainable growth and higher profits. We have pursued these investments while maintaining solid profitability and a strong balance sheet.”

Gross profit increased to approximately $3,600,000, or 72.7% of net revenues, for the three months ended June 30, 2011, and $13,778,000, or 72.5% of net revenues, for the fiscal year ended June 30, 2011. For the three months and fiscal year ended June 30, 2010, gross profit was approximately $2,698,000, or 74.4% of net revenues, and $10,378,000, or 72.6% of net revenues, respectively. The increase in gross profit dollars resulted primarily from the increase in sales volume. Gross profit percentage was consistent for the year ended 2011 from 2010. The slight decrease in gross profit percentage for the three-month period ended June 30, 2011 primarily resulted from lower reimbursement from the mix of referrals as compared to the three-month period ended June 30, 2010. Factors such as diagnoses that are not assured of reimbursement, along with insurance programs which present lower allowable reimbursement amounts (for example, state Medicaid programs) affect average reimbursement received on a short-term basis and tend to fluctuate margins slightly on a quarterly basis.

Operating expenses, which consist of selling, general, and administrative expenses and research and development expenses, were approximately $3,192,000 and $11,908,000, respectively, for the three months and fiscal year ended June 30, 2011, an increase of approximately 29.9% over total operating expenses for the three-month period last year and an increase of approximately 38.8% over total operating expenses for the 2010 fiscal year. These planned increases resulted from higher payroll and marketing expenses related to increasing the size of the sales team, patient training costs related to a higher sales volume, increased expenses relating to being a newly public company, and increased research and development expenses.

Total cash was approximately $4,092,000 as of June 30, 2011. For the fiscal year ended June 30, 2011, cash provided by financing activities was approximately $6,007,000, consisting of approximately $6,364,000 net proceeds received in August and September 2010 in connection with the Company’s initial public offering, $26,000 from exercise of warrants, and $60,000 in proceeds from subscription notes receivable. This was offset by principal payments on long-term debt of approximately $436,000. An aggregate of $1,111,000 was used for investing activities during the 2011 fiscal year, including $659,000 in payments for patent and trademark costs, primarily relating to defense of the SmartVest ® trademark, and $452,000 in net expenditures for property and equipment. The Company’s receivable position increased 45.9% to approximately $9,593,000, reflecting the significant sales growth over the past fiscal year.

About Electromed, Inc.Electromed, Inc., founded in 1992 and headquartered in New Prague, Minnesota, manufactures, markets, and sells products that provide airway clearance therapy, including the SmartVest ® Airway Clearance System and related products, to patients with compromised pulmonary function. Further information about the Company can be found at www.Electromed.com.

Cautionary Statements Certain statements found in this release may constitute forward-looking statements as defined in the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect the speaker’s current views with respect to future events and financial performance and include any statement that does not directly relate to a current or historical fact. The forward-looking statements in this release include those relating to the Company’s business strategy and intent to maximize long-term growth and profits. Forward-looking statements and the Company’s expectations regarding gross margins, and can generally otherwise be identified by the words “believe,” “expect,” “anticipate” or “intend” or similar words. Forward-looking statements cannot be guaranteed and actual results may vary materially due to the uncertainties and risks, known and unknown, associated with such statements. Examples of risks and uncertainties for Electromed include, but are not limited to, the impact of emerging and existing competitors, the effectiveness of our sales and marketing initiatives, the success of our research and development activities, changes to reimbursement programs, as well as other factors described from time to time in our reports to the Securities and Exchange Commission (including our Annual Report on Form 10-K). Investors should not consider any list of such factors to be an exhaustive statement of all of the risks, uncertainties or potentially inaccurate assumptions investors should take into account when making investment decisions. Shareholders and other readers should not place undue reliance on “forward-looking statements,” as such statements speak only as of the date of this release.
Electromed, Inc. and Subsidiary
Condensed Consolidated Balance Sheets
June 30 June 30
2011 2010
Assets (Unaudited)
Current Assets
Cash and cash equivalents $ 4,091,739 $ 610,727

Accounts receivable (net of allowances for doubtful accounts of $45,000)
9,593,105 6,577,002
Inventories 1,855,957 1,470,775
Prepaid expenses and other current assets 371,257 269,193
Deferred income taxes   722,000     514,000  
Total current assets 16,634,058 9,441,697
Property and equipment, net 2,807,082 2,688,941
Finite-life intangible assets, net 1,235,828 1,055,776
Deferred common stock offering costs - 828,034

Other assets
  191,964     128,789  
Total assets $ 20,868,932   $ 14,143,237  
Liabilities and Equity
Current Liabilities
Revolving line of credit $ 1,768,128 $ 1,768,128
Current maturities of long-term debt 438,267 397,886
Accounts payable 733,621 1,239,827
Accrued compensation 868,229 665,083
Warranty reserve 444,096 363,277
Other accrued liabilities   161,166     68,097  
Total current liabilities 4,413,507 4,502,298
Long-term debt, less current maturities 1,582,102 2,033,325
Deferred income taxes   167,000     145,000  
Total liabilities   6,162,609     6,680,623  
Commitments and Contingencies
Electromed, Inc. equity:
Common stock, $0.01 par value; authorized: 13,000,000 shares;
issued and outstanding: 8,100,485 and 6,187,885 shares, respectively 81,005 61,879
Additional paid-in capital 12,794,368 6,685,362
Retained earnings 1,853,450 797,873
Common stock subscriptions receivable for shares outstanding of
15,000 and 48,500 respectively   (22,500 )   (82,500 )
Total equity   14,706,323     7,462,614  
Total liabilities and equity $ 20,868,932   $ 14,143,237  
Electromed, Inc. and Subsidiary
Condensed Consolidated Statements of Income

    For the Three Months Ended     For the Fiscal Year Ended
June 30, June 30,
2011   2010 2011   2010
Net revenues $ 4,953,851 $ 3,624,168 $ 19,003,507 $ 14,303,848
Cost of revenues   1,353,463   926,439     5,226,001   3,925,557
Gross profit   3,600,388   2,697,729     13,777,506   10,378,291
Operating expenses
Selling, general and administrative 2,847,420 2,301,805 10,873,904 7,981,338
Research and development   344,333   155,522     1,033,693   600,986
Total operating expenses   3,191,753   2,457,327     11,907,597   8,582,324
Operating income 408,635 240,402 1,869,909 1,795,967
Interest expense, net of interest income of $2,112, $1,441, $10,923, and $6,417 respectively   40,403   57,754     191,332   263,431
Net income before income taxes 368,232 182,648 1,678,577 1,532,536
Income tax expense   (203,000 )   (112,000 )     (623,000 )   (599,000 )
Net income 165,232 70,648 1,055,577 933,536
Less: Net income attributable to non-controlling interest   -   -     -   (17,198

Net income attributable to Electromed, Inc. $ 165,232 $ 70,648 $   1,055,577 $ 916,338
Earnings per share attributable to Electromed, Inc. common shareholders:
Basic $ 0.02 $ 0.01 $   0.14 $ 0.15
Diluted $ 0.02 $ 0.01 $   0.13 $ 0.15
Weighted-average Electromed, Inc. common shares outstanding:
Basic   8,100,281   6,107,445     7,816,367   6,081,030
Diluted   8,117,883   6,145,076     7,841,006   6,114,919
Electromed, Inc. and Subsidiary
Condensed Consolidated Statements of Cash Flows
(Unaudited) For the Fiscal Year Ended
June 30,
2011     2010
Cash Flows From Operating Activities
Net income $ 1,055,577 $ 933,536

Adjustments to reconcile net income to net cash provided by (used in) operating activities:
Depreciation 335,620 298,928
Amortization of finite-life intangible assets 113,850 52,820
Amortization of debt issuance costs 31,463 53,404
Share-based compensation expense 156,169 168,895
Deferred income taxes (186,000 ) (149,000 )
Loss on disposal of property and equipment 26,225 4,258
Issuance of common stock for payment of services - 22,500
Changes in operating assets and liabilities:
Accounts receivable (3,016,103 ) (228,856 )
Inventories (385,182 ) (292,086 )
Prepaid expenses and other assets (193,342 ) (111,345 )
Accounts payable and accrued liabilities   646,619     (145,117 )
Net cash provided by (used in) operating activities   (1,415,104 )   607,937  
Cash Flows From Investing Activities
Expenditures for property and equipment (466,315 ) (269,616 )
Purchase of noncontrolling interest in Electromed Financial, LLC - (125,000 )
Expenditures for finite-life intangible assets (659,210 ) (514,505 )
Proceeds on the sale of fixed assets   14,812     -  
Net cash used in investing activities   (1,110,713 )   (909,121 )
Cash Flows From Financing Activities
Net borrowings (payments) on revolving line of credit - 1,768,128
Principal payments on long-term debt including capital lease obligations (435,968 ) (3,648,744 )
Proceeds from long-term debt - 2,520,000
Noncontrolling interest distributions paid - (18,417 )
Payments of deferred financing fees (6,716 ) (75,780 )
Proceeds from warrant exercises 25,800 390,832

Proceeds from sales of 1.9 million shares of common stock, net of offering costs of $1,236,287
6,363,713 -
Payments of deferred offering costs - (417,550 )
Proceeds from subscription notes receivable 60,000 9,000
Income tax benefit related to exercise of stock warrants   -     22,526  
Net cash provided by (used in) financing activities   6,006,829     549,995  
Net increase in cash and cash equivalents 3,481,012 248,811
Cash and cash equivalents
Beginning of period   610,727     361,916  
End of period $ 4,091,739   $ 610,727  

Copyright Business Wire 2010